NCT06195150Completed
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3 (actual)
- First submitted
- 22 Dec 2023
- Start date
- 8 Nov 2023
- Primary completion date
- 18 Jun 2025
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Kidney cancer
- NCT number
- NCT06195150
What you commit to
- Study type: Observational
- Participants enrolled: 3
- From 8 Nov 2023 to the primary completion date, 18 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Absence of surgery performance
Other
- Absence of VHL
- Quantity of kidney tumors \< 3
Who the study is looking for
- VHL syndrome
- Presence of at least 3 kidney tumors larger that 3cm to be surgically removed
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Ospedale San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.